CELC

MKT CAP:$6B

Celcuity Inc.

Market Cap

$6B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$113.56+$13.01 (+12.94%)

Apr 23, 2026

Company Details

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to...

CEO

Brian F. Sullivan

IPO Date

Sep 20, 2017

Website

www.celcuity.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$177M

EPS (Diluted)

-$3.78

Free Cash Flow

-$154M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 26, 2026

$0EPS -$3.78

Q4 2025

Mar 26, 2026

$0EPS -$0.96

Q3 2025

Nov 13, 2025

$0EPS -$0.92

Q2 2025

Aug 14, 2025

$0EPS -$1.04

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$8M
Q2 22	$0	$0	-$10M
Q3 22	$0	$0	-$11M
Q4 22	$0	$0	-$12M
Q1 23	$0	$0	-$13M
Q2 23	$0	$0	-$15M
Q3 23	$0	$0	-$19M
Q4 23	$0	-$27.9K	-$20M
Q1 24	$0	$0	-$22M
Q2 24	$0	$0	-$24M
Q3 24	$0	$0	-$30M
Q4 24	$0	-$35.3K	-$36M
Q1 25	$0	$0	-$36M
Q2 25	$0	$0	-$44M
Q3 25	$0	-$41.0K	-$43M
Q4 25	$0	$0	-$49M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$6M	-$6M
Q2 22	-$11M	-$11M
Q3 22	-$9M	-$9M
Q4 22	-$9M	-$10M
Q1 23	-$13M	-$13M
Q2 23	-$10M	-$10M
Q3 23	-$13M	-$13M
Q4 23	-$19M	-$19M
Q1 24	-$17M	-$17M
Q2 24	-$18M	-$18M
Q3 24	-$21M	-$21M
Q4 24	-$28M	-$28M
Q1 25	-$36M	-$36M
Q2 25	-$36M	-$36M
Q3 25	-$45M	-$45M
Q4 25	-$36M	-$36M

Capital Expenditures

Quarter	CapEx
Q1 22	$11.6K
Q2 22	$23.0K
Q3 22	$12.1K
Q4 22	$112.0K
Q1 23	$7.0K
Q2 23	$4.9K
Q3 23	$53.1K
Q4 23	$32.7K
Q1 24	$89.7K
Q2 24	$64.0K
Q3 24	$50.8K
Q4 24	$45.1K
Q1 25	$60.0K
Q2 25	$39.0K
Q3 25	$97.0K
Q4 25	$53.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+168.9%
Q2 22	—	-29.6%
Q3 22	—	+90.1%
Q4 22	—	+84.1%
Q1 23	—	+67.1%
Q2 23	—	+56.8%
Q3 23	—	+77.6%
Q4 23	—	+69.5%
Q1 24	—	+79.3%
Q2 24	—	+61.3%
Q3 24	—	+59.1%
Q4 24	—	+84.7%
Q1 25	—	+60.6%
Q2 25	—	+81.2%
Q3 25	—	+42.5%
Q4 25	—	+35.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$756.3K	—
Q2 22	$2M	—
Q3 22	$0	—
Q4 22	$1M	—
Q1 23	$0	—
Q2 23	$1M	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$0	—
Q2 24	$1M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$3M	—
Q3 25	$7M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 22	$7M	$811.3K	—	—
Q2 22	$8M	$1M	—	—
Q3 22	$10M	$1M	—	—
Q4 22	$11M	$1M	$278.8K	—
Q1 23	$11M	$1M	—	—
Q2 23	$14M	$1M	—	—
Q3 23	$17M	$1M	—	—
Q4 23	$18M	—	—	$2M
Q1 24	$21M	$2M	—	—
Q2 24	$22M	$2M	—	—
Q3 24	$28M	$2M	—	—
Q4 24	$33M	—	—	$3M
Q1 25	$32M	$4M	—	—
Q2 25	$40M	$4M	—	—
Q3 25	$35M	$8M	—	—
Q4 25	$38M	$12M	—	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$78M	$22.0K	$78M
Q2 22	$67M	$22.0K	$67M
Q3 22	$57M	$22.0K	$58M
Q4 22	$25M	$144M	$169M
Q1 23	$34M	$124M	$157M
Q2 23	$32M	$114M	$146M
Q3 23	$26M	$108M	$134M
Q4 23	$31M	$150M	$181M
Q1 24	$31M	$146M	$178M
Q2 24	$30M	$253M	$283M
Q3 24	$13M	$251M	$264M
Q4 24	$23M	$213M	$235M
Q1 25	$16M	$189M	$206M
Q2 25	$46M	$122M	$168M
Q3 25	$74M	$381M	$455M
Q4 25	$166M	$276M	$441M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	15M	+0.0%	+34.7%
Q2 22	15M	+0.1%	+18.4%
Q3 22	15M	+0.1%	+0.4%
Q4 22	17M	+12.9%	+13.2%
Q1 23	22M	+28.5%	+45.3%
Q2 23	22M	+1.3%	+47.1%
Q3 23	22M	+0.7%	+48.1%
Q4 23	29M	+30.7%	+71.3%
Q1 24	34M	+16.3%	+55.0%
Q2 24	38M	+14.4%	+75.1%
Q3 24	43M	+11.3%	+93.5%
Q4 24	43M	+0.2%	+48.4%
Q1 25	43M	+0.4%	+28.1%
Q2 25	44M	+1.4%	+13.6%
Q3 25	45M	+2.6%	+4.7%
Q4 25	53M	+17.3%	+22.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	39
Q2 22	$0	39
Q3 22	$0	39
Q4 22	$0	45
Q1 23	$0	45
Q2 23	$0	45
Q3 23	$0	45
Q4 23	$0	55
Q1 24	$0	55
Q2 24	$0	55
Q3 24	$0	55
Q4 24	$0	87
Q1 25	$0	87
Q2 25	$0	87
Q3 25	$0	87
Q4 25	$0	500

Revenue / Employee